Leo Pharma failed on the top line yet succeeded on profit in 2020

Leo Pharma's 2020 revenue did not quite reach DKK 11bn, but CEO Catherine Mazzacco notes that the firm has managed well in a Covid-19-impacted market. Now she looks forward to an eventful launch year.

Photo: Leo Pharma / PR

Like for many other companies, the coronavirus pandemic has had a heavy impact on Leo Pharma, and this is the primary factor in the company's having missed its 2020 revenue guidance.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs